 |
|
| Blog results | Results 1 - 10 of about 13,254 for vioxx naproxen. (0.25 seconds) |
| Sorted by relevance Sort by date |
| 15 Dec 2009 by Matt C. Bailey The trial court concluded that whether any particular plaintiff's loss can be measured by the difference in price between Vioxx and generic naproxen depends on issues specific to that individual plaintiff. The evidence supports the ... Bailey Class Action Daily - http://www.baileydaily.com/ |
| 1 Dec 2009 Investors had accused Merck of providing misleading information or omitting information about the risks of Vioxx. After a widely publicized study comparing Vioxx to naproxen, another pain reliever, found about five times more heart ... Drugs.com - Pharma News - http://www.drugs.com/news.html |
| 29 Nov 2009 by Anna Christensen First, in September 2001, the FDA made publicly available a Warning Letter in which it accused Merck & Co. of engaging in deceptive and misleading conduct with regard to the safety profile of Vioxx by endorsing the naproxen hypothesis. ... SCOTUSblog - http://www.scotusblog.com/wp/ - References |
| 27 Nov 2009 by Howard Brody For example, in the VIGOR (Vioxx Gastrointestinal Outcomes Research trial, the investigators compared Vioxx with naproxen, which according to Merck, has more gastrointestinal effects than many other non-selective NSAID. ... Hooked: Ethics, Medicine, and Pharma - http://brodyhooked.blogspot.com/ [ More results from Hooked: Ethics, Medicine, and Pharma ] |
| 11 Sep 2008 by FindLaw Staff ... Circuit stressed that a plausible alternative explanation for Vioxx patients' increased cardiovascular risk -- a theory that the court calls the "naproxen hypothesis” -- still existed on dates relevant to the statute of limitations. ... FindLaw's Common Law - http://commonlaw.findlaw.com/ [ More results from FindLaw's Common Law ] |
| 1 Dec 2009 by Jim Edwards March 2000: VIGOR results were released which showed better cardiovascular outcomes with naproxen over Vioxx. Investors found this information confusing because it was impossible to tell whether naproxen had CV benefits for users or ... Pharma Analysis RSS | BNET Industries - http://industry.bnet.com/pharma/blog/feed/rss/ |
| 1 Dec 2009 by Ed Silverman VIGOR wasn't placebo controlled . . . but it did show a statistically significant increase in risk for MI with Vioxx users. Merck claimed that Naproxen (the active comparator in the trial) decreased the risk, hence the disparity. ... Pharmalot - http://www.pharmalot.com/ - References [ More results from Pharmalot ] |
| 5 hours ago by admin Some studies indicate that glucosamine may facilitate as a lot of as nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin, ibuprofen, naproxen, and tolmetin in relieving symptoms of osteoarthritis, particularly within the knee, with fewer facet ... Typically, these are medication used to treat people with rheumatoid arthritis who have not versed NSAIDs or are not taking NSAIDs as a result of of the FDA recall of Vioxx, Celebrex, and Bextra (COX-2 inhibitors). ... Cures For Gout – Natural Treatments &... - http://www.curesforgout.net/ |
| 9 Nov 2009 by N. Peter Rasmussen A significant element of the claim involved a study of Vioxx and naproxen, a non-prescription pain reliever. The study showed a higher rate of heart problems for Vioxx users than for naproxen patients. However, Merck asserted that the ... Jim Hamilton's World of Securities Regulation - http://jimhamiltonblog.blogspot.com/ |
| 14 Dec 2009 Interestingly, you would consider the same factors whether you're re-considering Vioxx or Naproxen (recently found to cause heart problems) or Aryuvedic remedies (recently found to be associated with toxic levels of heavy metals). ... Search Tablets - http://searchtablets.com/ [ More results from Search Tablets ] |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
